Which has higher valuation and earnings, VOR or CPRX?

Catalyst Pharmaceuticals has higher revenue and earnings than Vor Biopharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Catalyst Pharmaceuticals $596.96M 6.46 $214.33M $1.74 18.10

Does the media prefer VOR or CPRX?

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Vor Biopharma. Catalyst Pharmaceuticals' average media sentiment score of 1.63 beat Vor Biopharma's score of 1.10 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Catalyst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Which has stronger valuation and earnings, VOR or RLAY?

Vor Biopharma has higher earnings, but lower revenue than Relay Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A Relay Therapeutics $10.68M 330.91 -$276.48M -$1.57 N/A

Is VOR or RLAY more profitable?

Vor Biopharma's return on equity of 0.00% beat Relay Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vor Biopharma N/A N/A N/A Relay Therapeutics N/A -43.94% -40.11%

Does the media favor VOR or RLAY?

In the previous week, Relay Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.10 beat Relay Therapeutics' score of 0.39 indicating that Vor Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Relay Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings & valuation, VOR or NAMS?

Vor Biopharma has higher earnings, but lower revenue than NewAmsterdam Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vor Biopharma N/A N/A N/A N/A N/A NewAmsterdam Pharma $22.57M 153.56 -$203.82M -$1.79 N/A

Does the media favor VOR or NAMS?

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 3 mentions for Vor Biopharma. NewAmsterdam Pharma's average media sentiment score of 1.10 beat Vor Biopharma's score of 1.10 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 5 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DNLI or VOR?

Vor Biopharma has lower revenue, but higher earnings than Denali Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Denali Therapeutics $330.53M 11.10 -$512.54M -$2.88 N/A Vor Biopharma N/A N/A N/A N/A N/A

Is DNLI or VOR more profitable?

Vor Biopharma's return on equity of 0.00% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Denali Therapeutics N/A -52.20% -43.86% Vor Biopharma N/A N/A N/A

Does the media favor DNLI or VOR?

In the previous week, Denali Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Denali Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.10 beat Denali Therapeutics' score of 0.71 indicating that Vor Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Denali Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, ADPT or VOR?

Vor Biopharma has lower revenue, but higher earnings than Adaptive Biotechnologies. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Adaptive Biotechnologies $276.98M 12.87 -$59.50M -$0.33 N/A Vor Biopharma N/A N/A N/A N/A N/A

Does the media refer more to ADPT or VOR?

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 3 mentions for Vor Biopharma. Adaptive Biotechnologies' average media sentiment score of 1.11 beat Vor Biopharma's score of 1.10 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vor Biopharma 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vor Biopharma (VOR) Competitors

$19.26 +0.28 (+1.48%)

Closing price 07/24/2026 04:00 PM Eastern

Extended Trading

$19.27 +0.01 (+0.05%)

As of 07/24/2026 07:34 PM Eastern

Compare

VOR vs. CPRX, RLAY, NAMS, DNLI, and ADPT

Should you buy Vor Biopharma stock or one of its competitors? MarketBeat compares Vor Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vor Biopharma include Catalyst Pharmaceuticals (CPRX), Relay Therapeutics (RLAY), NewAmsterdam Pharma (NAMS), Denali Therapeutics (DNLI), and Adaptive Biotechnologies (ADPT). These companies are all part of the "pharmaceutical products" industry.

How does Vor Biopharma compare to Catalyst Pharmaceuticals?

Vor Biopharma (NASDAQ:VOR) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk and media sentiment.

Vor Biopharma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its share price is 26% less volatile than the broader market.

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Catalyst Pharmaceuticals and 3 mentions for Vor Biopharma. Catalyst Pharmaceuticals' average media sentiment score of 1.63 beat Vor Biopharma's score of 1.10 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Catalyst Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Vor Biopharma currently has a consensus target price of $42.25, indicating a potential upside of 119.37%. Catalyst Pharmaceuticals has a consensus target price of $32.00, indicating a potential upside of 1.62%. Given Vor Biopharma's stronger consensus rating and higher possible upside, analysts plainly believe Vor Biopharma is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

Catalyst Pharmaceuticals has a net margin of 37.08% compared to Vor Biopharma's net margin of 0.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat Vor Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

97.3% of Vor Biopharma shares are owned by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are owned by institutional investors. 0.3% of Vor Biopharma shares are owned by company insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Catalyst Pharmaceuticals has higher revenue and earnings than Vor Biopharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Catalyst Pharmaceuticals	$596.96M	6.46	$214.33M	$1.74	18.10

Summary

Catalyst Pharmaceuticals beats Vor Biopharma on 7 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Relay Therapeutics?

Vor Biopharma (NASDAQ:VOR) and Relay Therapeutics (NASDAQ:RLAY) are both pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Vor Biopharma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, Relay Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

Vor Biopharma has higher earnings, but lower revenue than Relay Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
Relay Therapeutics	$10.68M	330.91	-$276.48M	-$1.57	N/A

In the previous week, Relay Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Relay Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.10 beat Relay Therapeutics' score of 0.39 indicating that Vor Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Relay Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by insiders. Comparatively, 5.0% of Relay Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Vor Biopharma's return on equity of 0.00% beat Relay Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
Relay Therapeutics	N/A	-43.94%	-40.11%

Vor Biopharma presently has a consensus price target of $42.25, indicating a potential upside of 119.37%. Relay Therapeutics has a consensus price target of $24.92, indicating a potential upside of 35.12%. Given Vor Biopharma's higher possible upside, equities research analysts clearly believe Vor Biopharma is more favorable than Relay Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
Relay Therapeutics	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.86

Summary

Vor Biopharma beats Relay Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Vor Biopharma compare to NewAmsterdam Pharma?

Vor Biopharma (NASDAQ:VOR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both pharmaceutical products companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Vor Biopharma has higher earnings, but lower revenue than NewAmsterdam Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vor Biopharma	N/A	N/A	N/A	N/A	N/A
NewAmsterdam Pharma	$22.57M	153.56	-$203.82M	-$1.79	N/A

Vor Biopharma has a beta of 1.69, meaning that its share price is 69% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

97.3% of Vor Biopharma shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 0.3% of Vor Biopharma shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, NewAmsterdam Pharma had 7 more articles in the media than Vor Biopharma. MarketBeat recorded 10 mentions for NewAmsterdam Pharma and 3 mentions for Vor Biopharma. NewAmsterdam Pharma's average media sentiment score of 1.10 beat Vor Biopharma's score of 1.10 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Vor Biopharma currently has a consensus target price of $42.25, indicating a potential upside of 119.37%. NewAmsterdam Pharma has a consensus target price of $49.42, indicating a potential upside of 66.72%. Given Vor Biopharma's higher probable upside, research analysts plainly believe Vor Biopharma is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

Vor Biopharma has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. Vor Biopharma's return on equity of 0.00% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vor Biopharma	N/A	N/A	N/A
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

Vor Biopharma and NewAmsterdam Pharma tied by winning 6 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Denali Therapeutics?

Denali Therapeutics (NASDAQ:DNLI) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, media sentiment, profitability and institutional ownership.

Vor Biopharma's return on equity of 0.00% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Denali Therapeutics	N/A	-52.20%	-43.86%
Vor Biopharma	N/A	N/A	N/A

Denali Therapeutics currently has a consensus price target of $35.17, indicating a potential upside of 52.17%. Vor Biopharma has a consensus price target of $42.25, indicating a potential upside of 119.37%. Given Vor Biopharma's higher possible upside, analysts clearly believe Vor Biopharma is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Denali Therapeutics has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

In the previous week, Denali Therapeutics had 2 more articles in the media than Vor Biopharma. MarketBeat recorded 5 mentions for Denali Therapeutics and 3 mentions for Vor Biopharma. Vor Biopharma's average media sentiment score of 1.10 beat Denali Therapeutics' score of 0.71 indicating that Vor Biopharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Denali Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

92.9% of Denali Therapeutics shares are held by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are held by institutional investors. 9.7% of Denali Therapeutics shares are held by company insiders. Comparatively, 0.3% of Vor Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Vor Biopharma has lower revenue, but higher earnings than Denali Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Denali Therapeutics	$330.53M	11.10	-$512.54M	-$2.88	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Summary

Vor Biopharma beats Denali Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Vor Biopharma compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Vor Biopharma (NASDAQ:VOR) are both pharmaceutical products companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Vor Biopharma has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -16.82%. Vor Biopharma's return on equity of 0.00% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Vor Biopharma	N/A	N/A	N/A

Adaptive Biotechnologies has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, Vor Biopharma has a beta of 1.69, meaning that its stock price is 69% more volatile than the broader market.

Vor Biopharma has lower revenue, but higher earnings than Adaptive Biotechnologies.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.87	-$59.50M	-$0.33	N/A
Vor Biopharma	N/A	N/A	N/A	N/A	N/A

In the previous week, Adaptive Biotechnologies had 5 more articles in the media than Vor Biopharma. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 3 mentions for Vor Biopharma. Adaptive Biotechnologies' average media sentiment score of 1.11 beat Vor Biopharma's score of 1.10 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vor Biopharma	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 97.3% of Vor Biopharma shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by insiders. Comparatively, 0.3% of Vor Biopharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Adaptive Biotechnologies presently has a consensus target price of $20.83, indicating a potential downside of 6.45%. Vor Biopharma has a consensus target price of $42.25, indicating a potential upside of 119.37%. Given Vor Biopharma's stronger consensus rating and higher probable upside, analysts plainly believe Vor Biopharma is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Vor Biopharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.82

Summary

Vor Biopharma beats Adaptive Biotechnologies on 7 of the 13 factors compared between the two stocks.

Get Vor Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VOR vs. The Competition

Export

Metric	Vor Biopharma	Biological Products, Except Diagnostic Substances Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$1.03B	$640.25M	$7.24B	$12.26B
Dividend Yield	N/A	N/A	40.99%	9.79%
P/E Ratio	N/A	N/A	23.62	23.64
Price / Sales	N/A	60.23	132.14	89.45
Price / Cash	N/A	N/A	165.01	59.64
Price / Book	N/A	2.52	12.77	6.07
Net Income	N/A	-$75.73M	$120.21M	$331.99M
7 Day Performance	6.47%	-1.46%	-0.98%	-0.63%
1 Month Performance	29.00%	12.75%	-2.00%	-2.00%
1 Year Performance	-56.23%	-77.48%	9.75%	13.62%

Vor Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VOR Vor Biopharma	2.8317 of 5 stars	$19.26 +1.5%	$42.25 +119.4%	-55.6%	$1.03B	N/A	N/A	140	Positive News
CPRX Catalyst Pharmaceuticals	4.415 of 5 stars	$31.49 flat	$32.00 +1.6%	N/A	$3.86B	$596.96M	18.10	80	News Coverage Short Interest Decrease
RLAY Relay Therapeutics	2.9544 of 5 stars	$19.91 +2.8%	$24.17 +21.4%	+401.1%	$3.81B	$10.68M	N/A	330	News Coverage Analyst Forecast
NAMS NewAmsterdam Pharma	2.9051 of 5 stars	$31.68 +2.0%	$49.00 +54.7%	+26.7%	$3.70B	$22.50M	N/A	4	News Coverage
DNLI Denali Therapeutics	2.6048 of 5 stars	$23.29 +2.5%	$35.08 +50.6%	+61.5%	$3.70B	$330.53M	N/A	430	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VOR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vor Biopharma (VOR) Competitors

VOR vs. CPRX, RLAY, NAMS, DNLI, and ADPT

How does Vor Biopharma compare to Catalyst Pharmaceuticals?

Summary

How does Vor Biopharma compare to Relay Therapeutics?

Summary

How does Vor Biopharma compare to NewAmsterdam Pharma?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Summary

How does Vor Biopharma compare to Adaptive Biotechnologies?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vor Biopharma (VOR) Competitors

VOR vs. CPRX, RLAY, NAMS, DNLI, and ADPT

How does Vor Biopharma compare to Catalyst Pharmaceuticals?

Which has more volatility and risk, VOR or CPRX?

Does the media prefer VOR or CPRX?

Do analysts prefer VOR or CPRX?

Is VOR or CPRX more profitable?

Do institutionals & insiders believe in VOR or CPRX?

Which has higher valuation and earnings, VOR or CPRX?

Summary

How does Vor Biopharma compare to Relay Therapeutics?

Which has more risk and volatility, VOR or RLAY?

Which has stronger valuation and earnings, VOR or RLAY?

Does the media favor VOR or RLAY?

Do institutionals and insiders have more ownership in VOR or RLAY?

Is VOR or RLAY more profitable?

Do analysts recommend VOR or RLAY?

Summary

How does Vor Biopharma compare to NewAmsterdam Pharma?

Which has better earnings & valuation, VOR or NAMS?

Which has more volatility and risk, VOR or NAMS?

Do insiders and institutionals have more ownership in VOR or NAMS?

Does the media favor VOR or NAMS?

Do analysts recommend VOR or NAMS?

Is VOR or NAMS more profitable?

Summary

How does Vor Biopharma compare to Denali Therapeutics?

Is DNLI or VOR more profitable?

Do analysts recommend DNLI or VOR?

Which has more volatility & risk, DNLI or VOR?

Does the media favor DNLI or VOR?

Do insiders & institutionals have more ownership in DNLI or VOR?

Which has preferable valuation & earnings, DNLI or VOR?

Summary

How does Vor Biopharma compare to Adaptive Biotechnologies?

Is ADPT or VOR more profitable?

Which has more risk & volatility, ADPT or VOR?

Which has better valuation & earnings, ADPT or VOR?

Does the media refer more to ADPT or VOR?

Do institutionals and insiders have more ownership in ADPT or VOR?

Do analysts rate ADPT or VOR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VOR vs. The Competition

Vor Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools